VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Since launching this latest addition to VIDA’s platform five months ago, demand has driven VIDA’s network to reach more than 1,000 sites, leading to substantially increased bookings and annual recurring revenue.
Financing was supported by Listwin Ventures, long-term customer UW Health, Mathers Associates, University of Iowa Research Foundation, Live Oak Bank (debt facility) as well as existing investors.
Recommended AI News: Microsoft Industry Cloud Could Be a Worthwhile Consideration, According to Info-Tech Research Group
“At VIDA, we are tapping into the growing biopharma market demand for clinical data intelligence to address inefficiencies and data quality issues in developing lung and respiratory therapies,” said Susan Wood, Ph.D., VIDA’s president & CEO. “The new funding supports strategic senior hires, builds on revenue momentum and accelerates the pace of innovation, particularly as biopharma companies seek new strategies to support the digitization, automation and decentralization of clinical trials.”
To broaden VIDA’s strategic opportunities and to support rapid commercial growth, Jon Freeman recently joined VIDA as chief financial officer. Freeman has a long track record of strategically guiding innovative healthcare companies through fundraising and acquisitions.
Recommended AI News: West Community Credit Union Chooses Lumin Digital To Provide Enhanced Digital Banking Services
“I’ve been fortunate to provide strategic financial counsel to some exciting growth companies,” said Freeman. “I was drawn to VIDA’s compelling value proposition, the team’s passion and commitment, and the company’s growth trajectory. The opportunity to build on that strong base was highly attractive.”
Other senior team members joining the team based on VIDA’s strong potential include Keshav Datta, Ph.D., vice president research & development; and Martin Henehan, vice president, business development. Collectively, Freeman, Datta and Henehan bring decades of experience building and growing financially successful biopharma and healthcare intelligence companies.
In early April 2022, VIDA received market authorization in Japan for its VIDA Insights software, which is a complementary data-driven solution used by lung care teams at the point of care, aiding them to detect disease early, diagnose with more confidence, make more personalized treatment decisions and use precision lung intelligence to better manage population health.
Recommended AI News: Infoworks Replicator Dramatically Accelerates On-Premises Hadoop Data Migration to the Cloud
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.